Endo's Oxymorphone Extended-Release Will Need New Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The additional clinical trial will address potential bias in the statistical analysis of the two fixed-dose Phase III efficacy trials. Endo expects to submit a revised NDA in 2005 following "approvable" letter.